Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyto-MSC
- Development stage
- Unknown
- Lead developer
- Cytopeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Cyto-MSC is an allogeneic cell therapy consisting of mesenchymal stem cells (MSCs) derived from the umbilical cord, developed by Cytopeutics Sdn. Bhd. It is primarily being investigated for the treatment of grade II-IV acute graft-versus-host disease (aGVHD) in patients who are receiving front-line corticosteroid therapy. The therapeutic mechanism involves the immunomodulatory properties of MSCs, which migrate to sites of inflammation and suppress the activation and proliferation of donor-derived alloreactive T-cells. This is achieved through the secretion of various anti-inflammatory mediators such as indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), and cytokines like IL-10 and TGF-beta, as well as direct cell-to-cell interactions, thereby reducing tissue damage and promoting immune tolerance.
- Brand names
- Cytopeutics
- Other names
- Cytopeutics umbilical cord mesenchymal stem cellsCytopeutics MSCUmbilical cord-derived mesenchymal stem cellsUC-MSC
Beyond the preview
Go deeper on Cyto-MSC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyto-MSC.